Evidence map›Paper›PMID 41735417›Full record

ArticleScientific reports2026

Preclinical efficacy and safety evaluation of a topical mesenchymal stem cell derived conditioned media gel for oral mucositis management.

Caroline Mathen, Wilfrid Dsouza, Deepali Sharma, Trupti Ninad Pradhan, Apeksha Kesarwani, Divya Gujar, Mangi Lal Choudhary, Aishwarya Nithyanand, Rutika Ghosalkar, Arvind Ingle and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Caroline MathenClinical R&D, OCT Therapies and Research Pvt Ltd Mumbai, Maharashtra, 400078, India. caroline@octtherapies.com.ORCID http://orcid.org/0000-0002-6324-9845
Wilfrid DsouzaClinical R&D, OCT Therapies and Research Pvt Ltd Mumbai, Maharashtra, 400078, India.ORCID http://orcid.org/0000-0002-4068-1264
Deepali SharmaSanctuary for Research and Development (sa-Ford) Raigad, Maharashtra, 410208, India.ORCID http://orcid.org/0009-0006-7776-0106
Trupti Ninad PradhanKode Lab, Tumor Immunology & Immunotherapy Group, Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India.ORCID http://orcid.org/0000-0001-5491-2070
Apeksha KesarwaniKode Lab, Tumor Immunology & Immunotherapy Group, Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India.
Divya GujarFacility for Immunomodulatory Activity Testing (FIAT), Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India.
Mangi Lal ChoudharySanctuary for Research and Development (sa-Ford) Raigad, Maharashtra, 410208, India.ORCID http://orcid.org/0009-0008-5707-3637
Aishwarya NithyanandClinical R&D, OCT Therapies and Research Pvt Ltd Mumbai, Maharashtra, 400078, India.ORCID http://orcid.org/0000-0003-3271-4617
Rutika GhosalkarClinical R&D, OCT Therapies and Research Pvt Ltd Mumbai, Maharashtra, 400078, India.ORCID http://orcid.org/0009-0003-4531-4732
Arvind IngleLaboratory Animal Facility, Animal Oncology Group, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, , Kharghar, Navi Mumbai, 410210, India.ORCID http://orcid.org/0000-0001-9201-9224
Pradip ChaudhariComparative Oncology Program & Translational Preclinical Imaging & Radiotherapy Facility, Animal Oncology Group,, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India.ORCID http://orcid.org/0000-0002-6792-7658
Jayant Sastri GodaDepartment of Radiation Oncology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India.ORCID http://orcid.org/0000-0002-3915-8927
Jyoti KodeKode Lab, Tumor Immunology & Immunotherapy Group, Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India. jkode@actrec.gov.in.ORCID http://orcid.org/0000-0001-6907-2449

Funding

OCT Therapies and Research Pvt Ltd. 5210
6 · The paper itself

Abstract

Chemotherapy / radiation induced oral mucositis (OM) poses significant clinical challenges, often leading to pain, malnutrition, treatment delays, and reduced quality of life. Regenerative medicine has been shown to have beneficial value in wound care. Hence, the current study was aimed at evaluating the safety and therapeutic efficacy of Mesenchymal Stem (Stromal) Cell derived Conditioned Media (MSC-CM) formulations (5%, 10%, and 15%) in preclinical models of 5-fluorouracil (5-FU)–induced OM and radiation wounds. The 28-day oral toxicity studies in rats/mice established that the formulations across treatment groups produced no treatment-related adverse effects. The NOAEL was established at 100% MSC-CM concentration. In the 5-FU based OM model, treatment with MSC-CM formulations demonstrated dose-dependent benefits, including significant reductions in ulcer size/ severity, regeneration of mucosal epithelium, and improvements in hematological, biochemical, hepatic, renal, and immunological parameters compromised by 5-FU. Histopathological evaluation revealed that chemotherapy-induced mucosal hyperplasia and blister formation were markedly reduced following MSC-CM treatment. These findings suggested enhanced tissue repair, possibly mediated through autophagy-associated mechanisms. The 15% formulation was most efficacious, yielding 100% survival, a mean ulcer healing score of 71.9%, and near-complete mucosal recovery, followed by 10% and 5% formulations. In the radiation wound healing model, administration of 10% and 15% MSC-CM formulations was well tolerated, as evidenced by stable body weights, and produced visible reductions in redness, hair loss, wound wetness, and oozing compared to controls. Notably, the 10% formulation promoted accelerated wound closure, with significant wound healing as early as day 4–7. Mechanistically, this could be attributed to induction of secretory IL-20 and IL-17 A/F in mice after wound healing gel (WHG) treatment at site of injury, which led to repair and regeneration of radiation-induced wounds. Collectively, these findings establish MSC-CM based topical formulations as safe and effective therapeutic candidates for mitigating chemotherapy and radiation induced toxicities, enhancing tissue regeneration, thereby supporting its translational potential in oral mucositis.

Indexed as

Mesenchymal Stem CellsStomatitisAdministration, TopicalAnimalsCulture Media, ConditionedDisease Models, AnimalFemaleFluorouracilGelsMaleMiceRatsWound HealingCulture Media, ConditionedFluorouracilGelsChemotherapy-induced injuryConditioned media formulationMesenchymal stromal cellsOral mucositisRadiationRegenerative medicineWound healing

Identifiers

PMID41735417
PMCPMC13031651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.